Oligodendroglioma: a neurological perspective in Sub-saharan Africa.
James E, Okon II, Akpan U, Abigail O.
Neurosurg Rev. 2024 Jul 13;47(1):321. doi: 10.1007/s10143-024-02579-7.
Oligodendroglioma: pathology, molecular mechanisms and markers.
Wesseling P, van den Bent M, Perry A.
Acta Neuropathol. 2015 Jun;129(6):809-27. doi: 10.1007/s00401-015-1424-1. Epub 2015 May 6.
Aggressive oligodendroglioma: a chemosensitive tumor.
Cairncross JG, Macdonald DR, Ramsay DA.
Neurosurgery. 1992 Jul;31(1):78-82. doi: 10.1227/00006123-199207000-00011.
[Oligodendroglioma, IDH Mutation and 1p/19q Codeletion].
Matsutani T.
No Shinkei Geka. 2023 Sep;51(5):811-820. doi: 10.11477/mf.1436204822.
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Engelhard HH, Stelea A, Mundt A.
Surg Neurol. 2003 Nov;60(5):443-56. doi: 10.1016/s0090-3019(03)00167-8.
Oligodendroglioma: pathology and molecular biology.
Engelhard HH, Stelea A, Cochran EJ.
Surg Neurol. 2002 Aug;58(2):111-7; discussion 117. doi: 10.1016/s0090-3019(02)00751-6.
Management of Low-Grade Gliomas.
Diaz M, Pan PC.
Cancer J. 2025 Jan-Feb 01;31(1):e0760. doi: 10.1097/PPO.0000000000000760.
Non-coding RNAs (ncRNAs) as therapeutic targets and biomarkers in oligodendroglioma.
Imran M, Altamimi ASA, Babu MA, Goyal K, Kaur I, Kumar S, Sharma N, Kumar MR, Alanazi FJ, Alruwaili AN, Aldhafeeri NA, Ali H.
Pathol Res Pract. 2024 Dec;264:155708. doi: 10.1016/j.prp.2024.155708. Epub 2024 Nov 6.
Secondary cerebellopontine angle oligodendroglioma after cranial irradiation: a case report and literature review.
Guo Z, Li D, Xie Y, Qian J, Zhao B.
Int J Neurosci. 2023 Apr;133(4):450-456. doi: 10.1080/00207454.2021.1929209. Epub 2022 May 23.
Treatment of oligodendroglioma: an update.
Paleologos NA, Cairncross JG.
Neuro Oncol. 1999 Jan;1(1):61-8.
